PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23079134-8	2012	Serum TRACP-5b was significantly increased during the follow-up period in the Bis + statin group, but only at 18 months in the Bis group.	Diphosphonates	78-81	acid phosphatase 5, tartrate resistant	Homo sapiens	6-14	
12631257-12	2003	TRACP-5b has also proved to be a useful new marker for monitoring bisphosphonates treatment in MM.	Diphosphonates	66-81	acid phosphatase 5, tartrate resistant	Homo sapiens	0-8	
18226993-9	2008	Our data suggest that bisphosphonates reduce TRACP 5b activity in the intertrochanteric area rather than in the anterior femoral head.	Diphosphonates	22-37	acid phosphatase 5, tartrate resistant	Homo sapiens	45-53	
26762133-6	2017	In addition, the patients in the switch-to-DMAb group showed a significant decrease compared to those in the switch-to-BP group in TRACP-5b (-55.8 vs. -32.8 %; P < 0.01) and ucOC (-85.5 vs. -65.0 %; P < 0.001), while no significant difference was observed in PINP (-67.5 vs. -62.1 %).	Diphosphonates	119-121	acid phosphatase 5, tartrate resistant	Homo sapiens	131-139	
35102444-19	2022	In the oral bisphosphonates group, the AUCs between TRACP-5b and PINP and TRACP-5b and CTX were significantly different, p < 0.01 and p = 0.001, respectively.	Diphosphonates	12-27	acid phosphatase 5, tartrate resistant	Homo sapiens	52-60	
35102444-19	2022	In the oral bisphosphonates group, the AUCs between TRACP-5b and PINP and TRACP-5b and CTX were significantly different, p < 0.01 and p = 0.001, respectively.	Diphosphonates	12-27	acid phosphatase 5, tartrate resistant	Homo sapiens	74-82	
33141482-11	2021	Serum bone-specific alkaline phosphatase and tartrate-resistant acid phosphatase 5b were significantly decreased in the BP-Dmab and SERM-Dmab groups compared with the BP-BP and SERM-SERM groups, respectively.	Diphosphonates	120-122	acid phosphatase 5, tartrate resistant	Homo sapiens	45-83	
27252739-3	2016	RESULTS: In drug-naive group (not received osteoporosis medications before the administration, n=70), the concomitant RLX or BP with ELD significantly decreased levels of TRACP-5b without severe suppression.	Diphosphonates	125-127	acid phosphatase 5, tartrate resistant	Homo sapiens	171-179	
27670281-10	2016	Moreover, the levels of P1NP (p=0.016) and TRACP-5b (p=0.015) were found to be significantly lower in patients with AFFs than in patients with TFFs in a subgroup analysis of BPs users.	Diphosphonates	174-177	acid phosphatase 5, tartrate resistant	Homo sapiens	43-51	
27252739-5	2016	CONCLUSION: ELD combined with RLX or BP administered for 6 months to postmenopausal women with osteoporosis who were drug-naive or who had switched medications significantly reduced and maintained TRACP-5b values within the reference range.	Diphosphonates	37-39	acid phosphatase 5, tartrate resistant	Homo sapiens	197-205